Worth reading
34Immaterial
Scored from 4 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Incoming appointee
29 itemsScheduled Appointment Date1 October 2026
Choudhury Kshendra (チョードリー クシェンドラ)
New position(Directly under the President) Executive Officer, Head of Business Development Department
Iino Kazuomi (飯野 一臣)
New position(Directly under the President) Head of Business Strategy Department
Yokoyama Hitoshi (横山 均)
New positionPharmaceuticals Division, Executive Officer, Head of Pharmaceuticals Division
Kunizawa Tomohiro (國澤 朋弘)
New positionPharmaceuticals Division, Head of Business Planning Department
Fujisawa Takashi (藤沢 隆司)
New positionPharmaceuticals Division, Head of Women's Health Sales Department
Matsuo Takanori (松尾 貴典)
New positionPharmaceuticals Division, Head of Specialty Care Sales Department
Suzuki Satoshi (鈴木 聡)
New positionGlobal Corporate Division, Director and Executive Vice President, Head of Global Corporate Division
Mitsuhashi Atsuya (三橋 厚弥)
New positionGlobal Corporate Division, Senior Executive Officer, Head of Corporate Planning Department
Uji Hiroshi (宇治 浩)
New positionGlobal Corporate Division, Executive Officer, Head of Finance Department
Okuda Mariko (奥田 真理子)
New positionGlobal Corporate Division, Executive Officer, Head of Human Resources and Governance Promotion Department
Maeda Takao (前田 貴生)
New positionGlobal Corporate Division, Human Resources and Governance Promotion Department, Head of HRBP
Shirao Atsuyuki (白尾 淳之)
New positionGlobal Corporate Division, Head of ICT Department
Naganawa Masayuki (長縄 正之)
New positionResearch and Development Division, Senior Executive Officer, Head of Research and Development Division
Nakashita Kei (中下 啓)
New positionResearch and Development Division, Head of Clinical Development Department
Kanayama Yoshinari (金山 良成)
New positionResearch and Development Division, Head of Research Department
Maeda Makoto (前田 真)
New positionResearch and Development Division, Head of Medical Affairs Department
Nozaki Takahiro (野崎 隆宏)
New positionProduction Division, Executive Officer, Head of Production Division
Matsuyama Sachiko (松山 幸子)
New positionProduction Division, Executive Officer, Head of Production Planning Department
Okushima Seiki (奥島 聖記)
New positionProduction Division, Head of Production Engineering Department
Yamamoto Keiichi (山本 圭一)
New positionProduction Division, Head of Tablet Manufacturing Department
Yoshisue Takanori (吉末 貴則)
New positionProduction Division, Head of Injectable Manufacturing Department
Tanaka Kazuhiro (田中 和浩)
New positionGeneral Manager, Production Control Department, Production Headquarters
Mochizuki Shizue (望月 しず恵)
New positionProduction Division, Head of Quality Control Department
Taguchi Takahiro (田口 貴浩)
New positionProduction Division, Head of GMP Management Department
Tonomura Yoshihide (殿村 吉秀)
New positionProduction Division, Head of Supply Chain Management Department
Sakurai Kazuhisa (桜井 和久)
New positionReliability Assurance Division, Executive Officer, Head of Reliability Assurance Division and Head of Safety Management Department
Mizuno Ayumi (水野 あゆみ)
New positionReliability Assurance Division, Head of Regulatory Affairs Department
Mizuguchi Nobuo (水口 円夫)
New positionReliability Assurance Division, Head of Quality Assurance Department
Sagara Takeshi (相良 岳史)
New positionOLIC (Thailand) Limited Managing Director
Reason for change
The organizational structure will be restructured to optimize the allocation of personnel and capital in line with the implementation of the Medium-Term Management Plan, with the aim of further strengthening and accelerating its initiatives.
Details of organizational changes
The Business Development Department and Business Strategy Department will be placed directly under the President. The Medical Affairs Department will be transferred from the Corporate Strategy Division to the Research and Development Division. The Corporate Planning Department and Corporate Administration Division will be integrated to establish the Global Corporate Division. The Corporate Administration Department will be reorganized into the Finance Department and the Human Resources and Governance Promotion Department, with an HRBP function established within the Human Resources and Governance Promotion Department.
| Item | Details |
|---|---|
| Scheduled Appointment Date | 1 October 2026 |
| Name of appointee | Choudhury Kshendra (チョードリー クシェンドラ), Iino Kazuomi (飯野 一臣), Yokoyama Hitoshi (横山 均), Kunizawa Tomohiro (國澤 朋弘), Fujisawa Takashi (藤沢 隆司), Matsuo Takanori (松尾 貴典), Suzuki Satoshi (鈴木 聡), Mitsuhashi Atsuya (三橋 厚弥), Uji Hiroshi (宇治 浩), Okuda Mariko (奥田 真理子), Maeda Takao (前田 貴生), Shirao Atsuyuki (白尾 淳之), Naganawa Masayuki (長縄 正之), Nakashita Kei (中下 啓), Kanayama Yoshinari (金山 良成), Maeda Makoto (前田 真), Nozaki Takahiro (野崎 隆宏), Matsuyama Sachiko (松山 幸子), Okushima Seiki (奥島 聖記), Yamamoto Keiichi (山本 圭一), Yoshisue Takanori (吉末 貴則), Tanaka Kazuhiro (田中 和浩), Mochizuki Shizue (望月 しず恵), Taguchi Takahiro (田口 貴浩), Tonomura Yoshihide (殿村 吉秀), Sakurai Kazuhisa (桜井 和久), Mizuno Ayumi (水野 あゆみ), Mizuguchi Nobuo (水口 円夫), Sagara Takeshi (相良 岳史) |
| Appointee's new position | (Directly under the President) Executive Officer, Head of Business Development Department, (Directly under the President) Head of Business Strategy Department, Pharmaceuticals Division, Executive Officer, Head of Pharmaceuticals Division, Pharmaceuticals Division, Head of Business Planning Department, Pharmaceuticals Division, Head of Women's Health Sales Department, Pharmaceuticals Division, Head of Specialty Care Sales Department, Global Corporate Division, Director and Executive Vice President, Head of Global Corporate Division, Global Corporate Division, Senior Executive Officer, Head of Corporate Planning Department, Global Corporate Division, Executive Officer, Head of Finance Department, Global Corporate Division, Executive Officer, Head of Human Resources and Governance Promotion Department, Global Corporate Division, Human Resources and Governance Promotion Department, Head of HRBP, Global Corporate Division, Head of ICT Department, Research and Development Division, Senior Executive Officer, Head of Research and Development Division, Research and Development Division, Head of Clinical Development Department, Research and Development Division, Head of Research Department, Research and Development Division, Head of Medical Affairs Department, Production Division, Executive Officer, Head of Production Division, Production Division, Executive Officer, Head of Production Planning Department, Production Division, Head of Production Engineering Department, Production Division, Head of Tablet Manufacturing Department, Production Division, Head of Injectable Manufacturing Department, General Manager, Production Control Department, Production Headquarters, Production Division, Head of Quality Control Department, Production Division, Head of GMP Management Department, Production Division, Head of Supply Chain Management Department, Reliability Assurance Division, Executive Officer, Head of Reliability Assurance Division and Head of Safety Management Department, Reliability Assurance Division, Head of Regulatory Affairs Department, Reliability Assurance Division, Head of Quality Assurance Department, OLIC (Thailand) Limited Managing Director |
| Reason for change | The organizational structure will be restructured to optimize the allocation of personnel and capital in line with the implementation of the Medium-Term Management Plan, with the aim of further strengthening and accelerating its initiatives. |
| Details of organizational changes | The Business Development Department and Business Strategy Department will be placed directly under the President. The Medical Affairs Department will be transferred from the Corporate Strategy Division to the Research and Development Division. The Corporate Planning Department and Corporate Administration Division will be integrated to establish the Global Corporate Division. The Corporate Administration Department will be reorganized into the Finance Department and the Human Resources and Governance Promotion Department, with an HRBP function established within the Human Resources and Governance Promotion Department. |
Items this document does not state (16)
Resolution dateDate of departureAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The organizational structure will be restructured to optimize the allocation of personnel and capital in line with the implementation of the Medium-Term Management Plan, with the aim of further strengthening and accelerating its initiatives.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.